Business Context and Reporting Period
Kiora Pharmaceuticals, Inc. (KPRX) filed a Form 8-K Current Report on September 8, 2026. The filing reports the appointment of a new senior executive effective as of the report date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Mr. Lane brings over 20 years of experience in ophthalmic clinical operations and regulatory strategy, having previously served as Chief Scientific Officer at Ora, Inc.
Compensation and Management Commentary
Under the Offer Letter dated June 22, 2026, Mr. Lane's compensation package includes:
- Base Salary: $350,000 annually.
- Sign-on Bonus: $75,000.
- Performance Bonus: Target of up to 35% of annual base salary.
- Equity Grant: Option to purchase up to 55,000 shares of common stock, subject to Board approval. Vesting occurs in one-third on the one-year anniversary, followed by equal monthly installments over two years.
The Company issued a press release regarding this appointment on September 8, 2026, which is incorporated by reference as Exhibit 99.1.
Investor Verification Checklist
- Verify the approval status of the 55,000 share option grant by the Compensation Committee.
- Review the full Offer Letter (Exhibit 10.1) for additional terms, conditions, or severance provisions not summarized in the 8-K.
- Confirm the impact of this leadership change on the Company's clinical development pipeline for ophthalmic therapies.